Follow us on:

MGC Pharmaceuticals on the front line of Psilocybin R&D (VIDEO)

MGC Pharmaceuticals plc (LON:MXC) CEO Roby Zomer joins DirectorsTalk Interviews to discuss the granting of its first import permit for 200g of Psilocybin Raw Mushroom material.

In this interview Roby reminds us of what the company does, explains what this first import of Psilocybin means for the company, takes us through some of the highlights from the last quarter and lets us know what investors can expect over the coming months.

MGC Pharmaceuticals is a European based pharmaceutical company specialising in the production and development of plant inspired medicines.

Find more news, interviews, share price & company profile here for:

Share this interview

Other Interviews

More News

MXC Capital Limited Good progress with investments and partnerships May 8, 2019
MXC Capital Limited Update re Offer for Tax Systems plc March 25, 2019
MXC Capital Limited Subscribes to additional Loan Notes in IDE Group Holdings plc February 12, 2019
MXC Capital Limited Significant developments during period November 28, 2018
MXC Capital Limited Now holds 29.98% of Adept4 Shares November 19, 2018
MXC Capital Limited Sells Castleton Shares for £5.5 million. August 30, 2018
MXC Capital Limited Further Investment in IDE Group Holdings plc July 31, 2018
Ravenscroft to acquire 25% of MXC Capital Limited July 19, 2018
MXC Capital Limited First Investment into Joint Venture with Liberty Global April 23, 2018

Search

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.